Thomas Conley, MD
Cardiovascular Disease · North Little Rock, ARNPI 1053384974
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 363 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 32 manufacturers reported payments, led by Shockwave Medical, Inc at 26.6% of the total.
Across 363 payments — averaging $32.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Shockwave Medical, Inc$3K
- Abiomed$3K
- Novartis$1K
- Boston Scientific$1K
- Abbott$778
- E.r. Squibb & Sons, L.L.C.$505
- plus $2K from 26 others
What the payments were for
- Travel & lodging$140%
- Food & beverage$11,928100%
- Education$200%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Shockwave Medical, Inc | 42 | $3,181 |
| Abiomed | 45 | $2,761 |
| Novartis | 91 | $1,375 |
| Boston Scientific | 23 | $1,143 |
| Abbott | 19 | $778 |
| E.r. Squibb & Sons, L.L.C. | 34 | $505 |
| AstraZeneca | 19 | $265 |
| Pfizer | 16 | $238 |
| Asahi Intecc USA, Inc. | 2 | $197 |
| Angiodynamics, Inc. | 1 | $188 |
| Merck | 10 | $178 |
| Biotronik Inc. | 2 | $164 |
| Johnson & Johnson | 12 | $158 |
| Amgen | 8 | $115 |
| Boehringer Ingelheim | 7 | $109 |
| Cardiovascular Systems Inc. | 6 | $104 |
| Cardiva Medical, Inc. | 2 | $76 |
| Sanofi-aventis U.S. LLC | 4 | $71 |
| Baxter Healthcare | 2 | $51 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $46 |
| Inari Medical, Inc. | 2 | $42 |
| Philips North America LLC | 1 | $36 |
| Novo Nordisk | 2 | $30 |
| Medtronic | 1 | $22 |
| Lexicon Pharmaceuticals, Inc. | 1 | $18 |
| Irhythm Technologies, Inc. | 1 | $18 |
| Esperion Therapeutics, Inc. | 1 | $17 |
| Elutia, Inc. | 1 | $16 |
| Bardy Diagnostics, Inc. | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $15 |
| Actelion Pharmaceuticals US, Inc. | 1 | $14 |
| Astellas Pharma US Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$1,730
- Impella$1,582
- COROFLOW$390
- CROSSBOSS$251
- AlphaVac$188
- STINGRAY$143
- Orsiro Mission$140
- PK Papyrus$140
- ASAHI PTCA Guide Wire$121
- GENERAL - THERAPIES$117
How this compares
$11,962 in reported general payments places this provider in the 80th percentile of 130 cardiovascular disease providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 841 | $723,012 |
| EntrestoSacubitril/Valsartan | 291 | $301,703 |
| XareltoRivaroxaban | 147 | $122,692 |
| BrilintaTicagrelor | 201 | $114,264 |
| JardianceEmpagliflozin | 67 | $60,427 |
| Praluent PenAlirocumab | 45 | $32,971 |
| Repatha SureclickEvolocumab | 35 | $30,659 |
| VascepaIcosapent Ethyl | 61 | $26,179 |
| Rosuvastatin Calcium | 748 | $10,957 |
| Atorvastatin Calcium | 899 | $8,949 |
| Repatha SyringeEvolocumab | 16 | $8,407 |
| Metoprolol Succinate | 528 | $8,047 |
| Nebivolol Hcl | 152 | $8,010 |
| Repatha PushtronexEvolocumab | 12 | $6,967 |
| Ranolazine ErRanolazine | 89 | $6,850 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $238 | $723,012841 claims |
| NovartisEntresto | $1,375 | $301,703291 claims |
| Johnson & JohnsonXarelto | $158 | $122,692147 claims |
| AstraZenecaBrilinta | $265 | $114,264201 claims |
| Boehringer IngelheimJardiance | $109 | $60,42767 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 130 cardiovascular disease providers in Arkansas.
Other cardiovascular disease in North Little Rock
- Mark St PierreNorth Little Rock$10K
- Morris KelleyNorth Little Rock$10K
- Marvin AshfordNorth Little Rock$7K
- Jay GeoghaganNorth Little Rock$6K
- Charles CaldwellNorth Little Rock$5K
- James ParkhurstNorth Little Rock$4K
- Ian CawichLittle Rock$294K
- Barry TedderJonesboro$130K
- Harvinder DodEl Dorado$126K
- William RollefsonLittle Rock$74K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.